Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients

References

• LeeDSAustinPCRouleauJLPredicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical modelJAMA20032902581258714625335
   PubMed Web of Science ®Google Scholar
• FallPJHyponatremia and hypernatremia: a systematic approach to causes and their correctionPostgrad Med2000107758210844943
   PubMed Web of Science ®Google Scholar
• GheorghiadeMHellkampASPinaILHemodynamic characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trialJ Am Coll Cardiol2005Suppl145A
   Google Scholar
• JanicicNVerbalisJGEvaluation and management of hypo-osmolality in hospitalized patientsEndocrinol Metab Clin North Am20033245948112800541
   PubMed Web of Science ®Google Scholar
• HawkinsRCAge and gender as risk factors for hyponatremia and hypernatremiaClin Chim Act2003337169172
   PubMed Web of Science ®Google Scholar
• SicaDASodium and water retention in heart failure and diuretic therapy: basic mechanismsCleve Clin J Med200673S2S716786906
   PubMedGoogle Scholar
• GoldsmithSRGheorghiadeMVasopressin antagonism in heart failureJ Am Coll Cardiol200546101785179116286160
   PubMed Web of Science ®Google Scholar
• SchrierRWBerlTAndersonRJOsmotic and nonosmotic control of vasopressin releaseAm J Physiol19792364F321F332373467
   PubMed Web of Science ®Google Scholar
• JardSMechanisms of action of vasopressin and vasopressin antagonistsKidney Int Suppl198826S38S422974096
   PubMed Web of Science ®Google Scholar
• VerbalisJGVasopressin V2 receptor antagonistsJ Mol Endocrinol2002291912200224
   PubMed Web of Science ®Google Scholar
• SicaDAHyponatremia and heart failure – pathophysiology and implicationsCongest Heart Fail20051127427716230871
   PubMedGoogle Scholar
• LeeWHPackerMPrognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failureCirculation1986732572673002660
   PubMed Web of Science ®Google Scholar
• RichMWBeckhamVWittenbergCLevenCLFreedlandKECarneyRMA multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failureN Engl J Med1995333119011957565975
   PubMed Web of Science ®Google Scholar
• KleinLO’ConnorCMLeimbergerJDLower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) studyCirculation20051112454256015867182
   PubMed Web of Science ®Google Scholar
• RusinaruDBuiciucOLeborgneLSlamaMMassyZTribouilloyCRelation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fractionAm J Cardiol200910340541019166698
   PubMed Web of Science ®Google Scholar
• GheorghiadeMAbrahamWTAlbertNMOPTIMIZE-HF Investigators and CoordinatorsRelationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registryEur Heart J200728898098817309900
   PubMed Web of Science ®Google Scholar
• GheorghiadeMRossiJSCottsWCharacterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trialArch Intern Med20071671998200517923601
   PubMed Web of Science ®Google Scholar
• GhaliJKHamadBYasothanUKirkpatrickPTolvaptanNat Rev Drug Discov2009861161219644472
   PubMed Web of Science ®Google Scholar
• ShoafSEBramerSLBricmontPZimmerCAPharmacokinetic and pharmacodynamic interaction between tolvaptan, an non-peptide AV antagonist and furosemide or hydrochlorothiazideJ Cardiovasc Pharmacol20075021321217703139
   PubMed Web of Science ®Google Scholar
• ShoafSEElizariMVWangZTolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmiasJ Cardiovasc Pharmacol Ther20051016517116211205
   PubMed Web of Science ®Google Scholar
• KondoKOgawaHYamashitaH7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active non-peptide arginine vasopressin V2 receptor antagonistBio org Med Chem1999717431754
   PubMed Web of Science ®Google Scholar
• HiranoTYamamuraYNakamuraSOnogawaTMoriTEffects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in ratsJ Pharmacol Exp Ther200029228829410604960
   PubMed Web of Science ®Google Scholar
• OhnishiAOritaYTakagiNAquaretic effect of a potent, orally active, non peptide V2 antagonist in menJ Pharmacol Exp Ther19952725465517853167
   PubMed Web of Science ®Google Scholar
• GheorghiadeMNiaziIOuyangJCzerwiecFKambayashiJOrlandiCTolvaptan investigatorsVasopressin receptor blockade in patients with congestive heart failure: results from a randomized, double-blind studyCirculation20031072690269612742979
   PubMed Web of Science ®Google Scholar
• GheorghiadeMGattisWAO’ConnorCMAcute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) InvestigatorsEffects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trialJAMA20042911963197115113814
   PubMed Web of Science ®Google Scholar
• RossiJBayramMUdelsonJEImprovement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trialAcute Card Care20079828617573581
   PubMedGoogle Scholar
• FilippatosGRossiJLloyd-JonesDMPrognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) studyJ Card Fail20071336036417602982
   PubMed Web of Science ®Google Scholar
• SchrierRWGrossPGheorghiadeMTolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremiaN Engl J Med2006552099211217105757
   PubMed Web of Science ®Google Scholar
• UdelsonJEMcGrewFFloresEMulticenter randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunctionJ Am Coll Cardiol2007492151215917543634
   PubMed Web of Science ®Google Scholar
• GheorghiadeMOrlandiCBurnettJCRationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)J Card Fail20051126026915880334
   PubMed Web of Science ®Google Scholar
• GheorghiadeMKonstamMABurnettJCJrEfficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) InvestigatorsShort-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status TrialsJAMA20072971332134317384438
   PubMed Web of Science ®Google Scholar
• KonstamMAGheorghiadeMBurnettJCJrEfficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) InvestigatorsEffects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome TrialJAMA20072971319133117384437
   PubMed Web of Science ®Google Scholar
• SternsRHNigwekarSUHixJKThe treatment of hyponatremiaSemin Nephrol20092928229919523575
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA labeling information FDA web site. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022275lbl. Accessed Jan 28, 2009.
   Google Scholar
• GhaliJKMechanisms, risks, and new treatment options for hyponatremiaCardiology200811114715718434717
   PubMed Web of Science ®Google Scholar
• GoldsmithSRTreatment options for hyponatremia in heart failureHeart Fail Rev200914657318777208
   PubMed Web of Science ®Google Scholar
• BraterDCDiuretic TherapyN Engl J Med19983393873959691107
   PubMed Web of Science ®Google Scholar
• GohKPManagement of hyponatremiaAm Fam Physician2004692387239415168958
   PubMed Web of Science ®Google Scholar
• LicataGDi PasqualePParrinelloGEffects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: Long-term effectsAm Heart J200314545946612660669
   PubMed Web of Science ®Google Scholar
• Costello-BoerrigterLCSmithWBBoerrigterGVasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamic or sodium and potassium excretion in human heart failureAm J Physiol Renal Physiol2006290F273F27816189291
   PubMed Web of Science ®Google Scholar
• GheorghiadeMGottliebSSUdelsonJETolvaptan InvestigatorsVasopressin V(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremiaAm J Cardiol2006971064106716563917
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration FDA labeling information. http://www.fda.gov/Drugs/default.htm. Accessed Jan 28, 2009.
   Google Scholar
• WongFBleiATBlendisLMThuluvathPJA vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo controlled trialHepatology20033718219112500203
   PubMed Web of Science ®Google Scholar
• AbrahamWTShamshirsazAAMcFannKOrenRMSchrierRWAquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patientsJ Am Coll Cardiol2006471615162116630999
   PubMed Web of Science ®Google Scholar
• THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation. http://www.clinicaltrials.gov. Accessed August 12, 2009.
   Google Scholar
• YatsuTTomuraYTaharaAPharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogsEur J Pharmacol19973212252309063692
   PubMed Web of Science ®Google Scholar
• TaharaATomuraYWadaKEffect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyteCardiovasc Res1998381982059683922
   PubMed Web of Science ®Google Scholar
• UdelsonJESmithWBHendrixGHAcute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failureCirculation20011042417242311705818
   PubMed Web of Science ®Google Scholar
• GhaliJKKorenMJTaylorJRfor the conivaptan study groupEfficacy and safety of oral conivaptan: A V1a/V2 vasopressin receptor antagonist, in patients with advanced heart failureJ Clin Endocrinol Metab2006912145215216522696
   PubMed Web of Science ®Google Scholar
• GoldsmithSRElkayamUHaughtWHBarveAHeWEfficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot studyJ Card Fail20081464164718926434
   PubMed Web of Science ®Google Scholar
• TEMPO 3/4 Trial Tolvaptan Efficacy and Safety in Management of Polycystic Kidney Disease and Its Outcomes (TEMPO3/4). http://www.clinicaltrials.gov/ct2/show/NCT00428948?term_TEMPO&rank_1. Accessed February 28, 2008.
   Google Scholar